Cytiva Fibro PrismA antibody purification technology

Monday, 12 October, 2020 | Supplied by: Global Life Sciences Solutions


Cytiva’s Fibro PrismA antibody purification technology has been designed to support the industry’s drive for increased speed and flexibility, in order to advance the development of novel therapeutics. The first product based on the company’s protein A fibre chromatography technology, it is being used to accelerate research for customers and collaborators.

Fibro chromatography technology enables rapid cycling antibody purification. In research and process development, this means Fibro PrismA can support up to 20 times increased throughput compared with traditional resins, the company claims. In clinical and commercial manufacturing, the technology will enable efficient single-use operations, by using the full unit lifetime in a single batch.

Fibro PrismA enables ultrafast purification in research and process development, allowing researchers to accelerate the drug discovery process. Clinical-scale products are set to follow.

Online: www.cytivalifesciences.com/en/au
Phone: 1800 150 522
Related Products

Yokogawa CellVoyager High-Content Analysis System CQ3000

The CellVoyager High-Content Analysis System CQ3000, by Yokogawa, can acquire high-resolution 3D...

Lumencor SPECTRA X Light Engine for multiplexed fluorescence detection

Lumencor's SPECTRA X Light Engine is recognised for its optical-breadboard-like versatility,...

Exum Instruments Massbox LALI-TOF-MS analytical device

Packaged into a compact, desktop instrument, the Massbox delivers quantitative analysis down to...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd